US 5158871A
· Rossomando et al.
· 1992
[cited by applicant]
US 6379666B1
· Tobinick
· 2002
[cited by applicant]
US 7727528B2
· Adcock
· 2010
[cited by applicant]
US 9623081B2
· Hawthorne
· 2017
[cited by examiner]
US 9907831B2
· Hawthorne
· 2018
[cited by examiner]
US 20040105821A1
· Bernstein et al.
· 2004
[cited by applicant]
US 20040115200A1
· Le et al.
· 2004
[cited by applicant]
US 20080075690A1
· Howell
· 2008
[cited by applicant]
US 20080277346A1
· Kirkland et al.
· 2008
[cited by applicant]
US 20110229556A1
· Irvine et al.
· 2011
[cited by applicant]
US 20120108787A1
· Lue
· 2012
[cited by applicant]
US 20120141797A1
· Sherman et al.
· 2012
[cited by applicant]
US 20130195972A1
· Manku et al.
· 2013
[cited by applicant]
US 20130337070A1
· Brenneisen et al.
· 2013
[cited by applicant]
US 20140220133A1
· Paciotti et al.
· 2014
[cited by applicant]
US 20140296836A1
· Shen et al.
· 2014
[cited by applicant]
US 20140341975A1
· Livneh
· 2014
[cited by applicant]
US 20150112842A1
· Sieger et al.
· 2015
[cited by applicant]
US 20150231233A1
· Lentz
· 2015
[cited by applicant]
US 20170038382A1
· Hawthorne
· 2017
[cited by applicant]
US 20170056327A1
· Mi et al.
· 2017
[cited by applicant]
US 20180256747A1
· Hawthorne et al.
· 2018
[cited by applicant]
US 20190248885A1
· Liddelow et al.
· 2019
[cited by applicant]
US 20240269319A1
· Hawthorne et al.
· 2024
[cited by applicant]
CA 2458682A1
· 2003
[cited by applicant]
CA 202248682
· 2003
[cited by examiner]
CN 101123990A
· 2008
[cited by applicant]
CN 106999550A
· 2017
[cited by applicant]
CN 107837389A
· 2018
[cited by applicant]
DE 10144251A1
· 2003
[cited by applicant]
EP 1174129A1
· 2002
[cited by applicant]
EP 1227843A2
· 2002
[cited by applicant]
EP 1949915A2
· 2008
[cited by applicant]
JP 2017530198A
· 2017
[cited by applicant]
WO WO0137873A2
· 2001
[cited by applicant]
WO WO0149321A1
· 2001
[cited by applicant]
WO WO2004071641A2
· 2004
[cited by applicant]
WO WO2004094613A2
· 2004
[cited by applicant]
WO WO2005009602A2
· 2005
[cited by applicant]
WO WO2005107802A2
· 2005
[cited by applicant]
WO WO2006014646A2
· 2006
[cited by applicant]
WO WO2006086428A2
· 2006
[cited by applicant]
WO WO2008021908A2
· 2008
[cited by applicant]
WO WO2008041774A1
· 2008
[cited by applicant]
WO WO2008127515A1
· 2008
[cited by applicant]
WO WO2009030492A2
· 2009
[cited by applicant]
WO WO2009061853A2
· 2009
[cited by applicant]
WO WO2009076673A2
· 2009
[cited by applicant]
WO WO2009126920A2
· 2009
[cited by applicant]
WO WO2010042555A2
· 2010
[cited by applicant]
WO WO2010082910A1
· 2010
[cited by applicant]
WO WO2011084620A2
· 2011
[cited by applicant]
WO WO2012163544A1
· 2012
[cited by applicant]
WO WO2013029278A1
· 2013
[cited by applicant]
WO WO2013030831A2
· 2013
[cited by applicant]
WO WO2013052167A2
· 2013
[cited by applicant]
WO WO2013059831A1
· 2013
[cited by applicant]
WO WO2013179143A2
· 2013
[cited by applicant]
WO WO2014013473A1
· 2014
[cited by applicant]
WO WO2014041544A1
· 2014
[cited by applicant]
WO WO2014109842A2
· 2014
[cited by applicant]
WO WO2014128225A1
· 2014
[cited by applicant]
WO WO2015054659A1
· 2015
[cited by applicant]
WO WO2015112842A1
· 2015
[cited by applicant]
WO WO2016054522A1
· 2016
[cited by applicant]
WO WO2017004159A1
· 2017
[cited by applicant]
WO WO2017019949A1
· 2017
[cited by applicant]
WO WO2017176762A1
· 2017
[cited by applicant]
WO WO2018129188A1
· 2018
[cited by applicant]
WO WO2018129207A1
· 2018
[cited by applicant]
Danhier et al., “PLGA-based nanoparticles: an overview of biomedical applications.” Journal of Controlled Release 161 (2012): 505-522.
[cited by applicant]
Fang et al., “In vivo tumor targeting of tumor necrosis factor-α-loaded stealth nanoparticles: Effect of MePEG molecular weight and particle size.” European Journal of Pharmaceutical Sciences 27 (2006): 27-36.
[cited by applicant]
Aderka et al., “Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients,” Cancer Res, 51(20): 5602-5607 (1991).
[cited by applicant]
Akdis et al., “Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases.” Journal of Allergy and Clinical Immunology 127(3): 701-721 (2011).
[cited by applicant]
Anand, “Exosomal membrane molecules are potent immune response modulators,” Communicative & Integrative Biology, 3(5): 405-408 (2010).
[cited by applicant]
Andersen et al., “Production technologies for monoclonal antibodies and their fragments.” Current Opinion in Biotechnology 15(5): 456-462 (2004).
[cited by applicant]
Balamurugan et al., “Surface immobilization methods for aptamer diagnostic applications,” Anal Bioanal Chem, 390: 1009-1021 (2008).
[cited by applicant]
Bork, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,” Genome Research, 10:398-400 (2000).
[cited by applicant]
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science, 247:1306-1310 (1990).
[cited by applicant]
Boyer et al., “An Overview of protein-polymer particles,” Soft Matter, 7: 1599-1614 (2011).
[cited by applicant]
Brown et al., “Tolerance of Single, but Not Multiple, Amino Acid Replacements in Antibody VH CDR2: a Means of Minimizing B Cell Wastage From Somatic Hypermutation?” J Immunol, 156(9):3285-3291 (1996).
[cited by applicant]
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single…
[cited by applicant]
Cauda et al., “Multiple core shell functionalized colloidal mesoporous silica nanoparticles,” J American Chem Society, 131(32): 11361-11370 (2009).
[cited by applicant]
Charych et al., “NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models,” Clin Cancer Res, 22(3):680-690 (2016).
[cited by applicant]
Cheng et al., “Enhanced Uptake of Porous Silica Microparticles by Bifunctional Surface Modification with a Targeting Antibody and a Biocompatible Polymer,” ACS Applied Materials & Interfaces, 2(9): 2489-2495 (2010).
[cited by applicant]
Clark et al., “Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases,” J Med Chem, 57(12):5023-5038 (2014).
[cited by applicant]
Costamagna et al., “Complexes of macrocycles with pendant arms as models for biological molecules,” Coordination Chemistry Reviews, 196: 125-164 (2000).
[cited by applicant]
De Wever et al., “Soluble cadherins as cancer biomarkers,” Clin Exp Metastasis, 24: 685-697 (2007).
[cited by applicant]
Dickschat et al., “Preparation of Bifunctional Mesoporous Silica Nanoparticles by Orthogonal Click Reactions and Their Application in Cooperative Catalysis” Chem. Eur. J. 18: 16689-16697 (2012).
[cited by applicant]
Dinarello, “Historical insights into cytokines.” European Journal of Immunology 37.S1 (2007): S34-S45.
[cited by applicant]
Douglas et al., “Self-assembly of DNA into nanoscale three-dimensional shapes,” Nature, 459(7245):414-418 (2009).
[cited by applicant]
Duffy et al., “The ADAMs: New Therapeutic Targets for Cancer?” Cancer Targeted Drug Delivery. Springer New York, 273-287 (2013).
[cited by applicant]
Extended European Search Report for EP Application No. 15845555.0 dated Apr. 24, 2018.
[cited by applicant]
Extended European Search Report for EP Application No. 16818651.8 mailed Jan. 31, 2019.
[cited by applicant]
Extended European Search Report issued by the European Patent Office in corresponding Application No. 15740254.6, dated Dec. 20, 2017.
[cited by applicant]
Extended European Search Report received for EP Patent Application No. EP16831405.2, dated Feb. 5, 2019.
[cited by applicant]
Fischer et al., “A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death,” PLoS One, 6(11):e27621 (2011).
[cited by applicant]
Giai et al. “Shedding of Tumor Necrosis Factor Receptor 1 Induced by Protein A Decreases Tumor Necrosis Factor Alpha Availability and Inflammation during Systemic
[cited by applicant]
Giret et al., “Mesoporous-Silica-Functionalized Nanoparticles for Drug Delivery” Chem. Eur. J. 21:13850-13865 (2015).
[cited by applicant]
Grivennikov et al., “Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage.” Annals of the rheumatic diseases 70.Suppl 1 (2011):i104-i108.
[cited by applicant]
Guicciardi et al., “Life and death by death receptors,” The FASEB Journal, 23(6): 1625-1637 (2009).
[cited by applicant]
Guido et al., “Virtual Screening and Its Integration with Modern Drug Design Technologies,” Curr Med Chem, 15(1):37-46 (2008).
[cited by applicant]
Guthrie et al., “Assays for cytokines using aptamers.” Methods 38.4 (2006): 324-330.
[cited by applicant]
Han et al., “TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NF-?B through TNF receptor-associated factors.” Biochemical and Biophysical Research Communications 305 (2003): 7…
[cited by applicant]
Hey et al., “Artificial, non-antibody binding proteins for pharmaceutical and industrial applications,” Trends in Biotechnology, 23(10): 514-522 (2005).
[cited by applicant]
Holtan et al. “Cancer and Pregnancy: Parallels in Growth, Invasion, and Immune Modulation and Implications for Cancer Therapeutic Agents”, Mayo Clinical Protocols, 84(11): 985-1000 (2009).
[cited by applicant]
Hruby et al., “Design of Peptide and Peptidomimetic Ligands with Novel Pharmacological Activity Profiles,” Annu Rev Pharmacol Toxicol, 53: 557-580 (2013).
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2017/025954 issued Oct. 9, 2018.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2018/012414 mailed Jul. 9, 2019.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2015/012653 dated Apr. 23, 2015.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2015/053748 dated Dec. 28, 2015.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/040022 dated Aug. 23, 2016.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/044674 mailed Oct. 13, 2016.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/025954 dated Sep. 8, 2017.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2018/012386, dated Mar. 28, 2018.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2018/012414, dated Mar. 28, 2018.
[cited by applicant]
Jiang et al., “Biomolecule-functionalized polymer brushes,” Chem. Soc. Rev., 42: 3394-3426 (2013).
[cited by applicant]
Kohga et al., “Anticancer Chemotherapy Inhibits MHC Class I-Related Chain A Ectodomain Shedding by Downregulating ADAM10 Expression in Hepatocellular Carcinoma,” Cancer Res, 69: 8050-8057 (2009).
[cited by applicant]
Kraut, “How do enzymes work ?. ” Science 242(4878): 533-540 (1988).
[cited by applicant]
Lazar et al., “Transforming Growth Factor alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Mol Cell Biol, 8:1247-1252 (1988).
[cited by applicant]
Lentz et al., “Reduction of plasma levels of soluble tumor necrosis factor and interleukin-2 receptors by means of a novel immunoadsorption column,” Ther Apher Dial, 12(6):491-499 (2008).
[cited by applicant]
Lentz, “The role of therapeutic apheresis in the treatment of cancer: a review,” Ther Apher, 3(1):40-49 (1999).
[cited by applicant]
Li et al., “PEGylated recombinant human tumor necrosis factor alpha: preparation and anti-tumor potency,” Acta Pharmacol Sin, 22(6):549-555 (2001).
[cited by applicant]
Liu et al., “Engineered interleukin-2 antagonists for the inhibition of regulatory T cells,” J Immunother, 32(9):887-894 (2009).
[cited by applicant]
Ma et al., “Modular and Orthogonal Post-PEGylation Surface Modifications by Insertion Enabling Penta-functional Ultrasmall Organic-Silica Hybrid Nanoparticles” Chemistry of Materials 29(16):6840-6855 (2017).
[cited by applicant]
“Magnetic Nanoparticle Biospleen Device for Sepsis Therapy,” Wyss Institute for Biology Inspired Engineering at Harvard, http://www.nanowerk.com/nanotechnology-news/newsid=37354.php (pp. 1-8).
[cited by applicant]
Marleau et al., “Exosome removal as a therapeutic adjuvant in cancer,” Journal of Translational Medicine, 10: 134 (2012).
[cited by applicant]
Mascini et al., “Nucleic acid and peptide aptamers: fundamentals and bioanalytical aspects.” Angewandte Chemie International Edition 51: 1316-1332 (2012).
[cited by applicant]
Mout et al., “Surface functionalization of nanoparticles for nanomedicine,” Chem Soc Rev, 41(7):2539-2544 (2012).
[cited by applicant]
Mullberg et al., “A Metalloprotease Inhibitor Blocks Shedding of the IL-6 Receptor and the p60 TNF Receptor,” J Immunol, 155: 5198-5205 (1995).
[cited by applicant]
Muntasell et al., “T cell-induced secretion of MHC class II-peptide complexes on B cell exosomes,” The EMBO Journal, 26: 4263-4272 (2007).
[cited by applicant]
Novick et al., “The tale of soluble receptors and binding proteins: From bench to bedside.” Cytokine & Growth Factor Reviews 18: 525-533 (2007).
[cited by applicant]
Okuyama R.; Uhara K., “Functions of exosome in melanoma,” Japanese journal of clinical medicine, 71: 98-102 (2013).
[cited by applicant]
Parker Annual Report 2014.
[cited by applicant]
Partial Supplementary European Search Report issued by the European Patent Office in corresponding Application No. EP 15740254.6, dated Sep. 25, 2017.
[cited by applicant]
Pazos et al., “DNA Recognition by Synthetic Constructs,” ChemBioChem, 12: 1958-1973 (2011).
[cited by applicant]
Porschewski et al., “Using Aptamers as Capture Reagents in Bead-Based Assay Systems for Diagnostics and Hit Identification,” Journal of Biomolecular Screening, 11(7): 773-781 (2006).
[cited by applicant]
Qhobosheane et al., “Biochemically functionalized silica nanoparticles,” Analyst, 126:1274-1278 (2001).
[cited by applicant]
Richter et al., “Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc,” MABS, 11(4):653-665 (2019).
[cited by applicant]
Rowe et al., “Novel TNF receptor-1 inhibitors identified as potential therapeutic candidates for traumatic brain injury,” Journal of Neuroinflammation, 15:154 (2018).
[cited by applicant]
Selectin Wikipedia Article; retrieved online <https://en.wikipedia.org/wiki/Selectin>: 8 pages (Mar. 20, 2020).
[cited by applicant]
Sheu et al., “A Novel Role of Metalloproteinase in Cancer-mediated Immunosuppression,” Cancer Res, 61: 237-242 (2001).
[cited by applicant]
Skerra et al., “Alternative non-antibody scaffolds for molecular recognition,” Current Opinion in Biotechnology, 18: 295-304 (2007).
[cited by applicant]
Sperling et al., “Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles,” Philosophical Transactions of the Royal Society A, 368: 1333-1383 (2010).
[cited by applicant]
Subbiah et al., “Nanoparticles: Functionalization and Multifunctional Applications in Biomedical Sciences,” Current Medicinal Chemistry, 17:4559-4577 (2010).
[cited by applicant]
Thery et al., “Exosomes: Composition, Biogenesis and Function,” Nature Reviews Immunology, 2: 569-579 (2002).
[cited by applicant]
Vajdos et al., “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,” J. Mol. Biol., 320(2): 415-428 (2002).
[cited by applicant]
Waldmann, “Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey,” J Clin Immunol, 27(1):1-18 (2007).
[cited by applicant]
Walter et al., “Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells.”
[cited by applicant]
Williams et al., “Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both P55 and P75 TNF receptor shedding and TNFα processing in RA synovial membrane cell cultures,” J Clin Invest, 97(12):2833-…
[cited by applicant]
Xing et al., “Immobilization of biomolecules on the surface of inorganic nanoparticles for biomedical applications,” Sci. Technol. Adv. Mater., 11: 014101 (2010).
[cited by applicant]
Yang et al., “The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma,” Cancer, 76(4):687-694 (1995).
[cited by applicant]
Yousef et al. “Systemic Attenuation of the TGF-β Pathway by a Single Drug Simultaneously Rejuvenates Hippocampal Neurogenesis and Myogenesis in the same old Mammal,” Oncotarget, 6(14):11959 (2015).
[cited by applicant]
Zhao et al., “Aptamer Capturing of Enzymes on Magnetic Beads to Enhance Assay Specificity and Sensitivity,” Analytical Chemistry, 83: 9234-9236 (2011).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US25/42389 dated Oct. 30, 2025.
[cited by applicant]
Howard et al., “Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm”, ACS Nano 8.5: 4100-4132 (2014).
[cited by applicant]